Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma

Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma

By the implementation of the anti-PD-1 antibody pembrolizumab and given its possible synergy with RT, the aim of the present trial is to develop a chemotherapy-free first-line treatment for patients with newly diagnosed early-stage favorable cHL.

Inclusion Criteria:

• Histologically proven first diagnosis of cHL

• Stage I-II without risk factors

  • Large mediastinal mass
  • Extranodal involvement
  • Elevated erythrocyte sedimentation rate (ESR)
  • Involvement of ≥ 3 nodal areas

Exclusion Criteria:

• Central nervous system lymphoma, nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma,
• Prior cHL-directed treatment
• Prior chemotherapy, RT or allogeneic stem cell/solid organ transplant
• Prior or concurrent disease precluding protocol treatment (for details see section 4.2)
• Pregnancy or breastfeeding
• Non-compliance